Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC) Meeting Abstract

  

Authors:	Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Sarrio, R. G.; Ribe, S. G.; Wu, J.; Schmidt, E. V.; Perini, R. F.; Kubiak, P.; Smith, A. D.; Motzer, R. J.
Abstract Title:	Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)
Meeting Title:	56th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	38
Issue:	15 Suppl.
Meeting Dates:	2020 May 29-31
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2020-05-20
Start Page:	279s
Language:	English
ACCESSION:	WOS:000560368302265
PROVIDER:	wos
DOI:	10.1200/JCO.2020.38.15_suppl.5008
Notes:	Meeting Abstract: 5008 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/172915